secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0001193125-24-032160
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir receives Nasdaq notice of non-compliance; bid price below $1.00 for 30 days
--------------------------------------------------------------------------------

- Received Nasdaq letter on Feb 9, 2024, for bid price < $1.00 over 30 consecutive business days.
- Has 180 days (until Aug 7, 2024) to regain compliance by closing at $1.00+ for 10 consecutive days.
- If not compliant, may get additional 180 days if certain criteria are met.
- Evaluating options including reverse stock split to regain compliance.
- Common stock continues trading on Nasdaq Global Select under symbol ALVR for now.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312524032160/0001193125-24-032160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312524032160/d764004d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-032160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer